BioTuesdays

Author - Shane Matte

Vital Therapies Logo
Markets

Vital Therapies prices $35-million stock offering

Vital Therapies (NASDAQ:VTL) has priced a public offering of 8,750,000 newly issued common shares at a price of $4 each for gross proceeds of approximately $35-million. Vital also granted the underwriters a 30-day...

March 22, 2017
Checkpoint Therapeutics
Markets

Ladenburg starts Checkpoint Therapeutics at buy

Ladenburg Thalmann initiated coverage of Checkpoint Therapeutics (OTCQX:CKPT) with a “buy” rating and $20 price target. The stock closed at $13 on March 21. CKPT focuses on combination treatments for solid tumors based...

March 22, 2017
Proteon Therapeutics
Markets

HCW downgrades Proteon to neutral

H.C. Wainwright downgraded Proteon Therapeutics (NASDAQ:PRTO) to “neutral” from “buy” and slashed its price target to $3 from $18, citing a lack of major catalysts that will likely render the shares range-bound. The...

March 17, 2017
3D Signatures
Developments

3DS makes final patent payment

3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) recently made the final payment to CancerCare Manitoba (CCMB) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS in June 2014. Quarterly...

March 14, 2017
Profound Medical Logo
Markets

Profound Medical to list on OTCQX

Shares of Profound Medical (TSX-V:PRN) will be eligible for trading on the OTCQX Best Market under the symbol, PRFMF, effective at the open on March 13. “The U.S. is a key target market for the TULSA-PRO system...

March 10, 2017
RepliCel Life Sciences
Developments

RepliCel pursuing non-diluting grant funding

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP; FRA:P6P2) has retained The FreeMind Group, an international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private...

March 7, 2017
AxoGen
Markets

Roth starts AxoGen at buy

Roth Capital Partners initiated coverage on AxoGen (NASDAQ:AXGN) with a “buy” rating and target price of $14.50. The stock closed at $10 on March 3. “Driven by increased market awareness, surgeon education, clinical...

March 6, 2017
STAAR Surgical
Markets

Canaccord ups STAAR Surgical price target to $9

Canaccord Genuity raised its price target for STAAR Surgical (NASDAQ:STAA) to $9 from $7, but maintained its “hold” rating after the company reported fourth quarter results. The stock closed at $10.18 on March 2. STAAR...

March 3, 2017